Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 323

1.

Genotype-specific mutations in the polymerase gene of hepatitis B virus potentially associated with resistance to oral antiviral therapy.

Mirandola S, Sebastiani G, Rossi C, Velo E, Erne EM, Vario A, Tempesta D, Romualdi C, Campagnolo D, Alberti A.

Antiviral Res. 2012 Dec;96(3):422-9. doi: 10.1016/j.antiviral.2012.09.014. Epub 2012 Sep 28.

PMID:
23026293
2.

Hepatitis B virus with the rtL80V/I mutation is associated with a poor response to adefovir dipivoxil therapy.

Lee YS, Chung YH, Kim JA, Kim SE, Shin JW, Kim KM, Lim YS, Park NH, Lee HC, Lee YS, Suh DJ.

Liver Int. 2009 Apr;29(4):552-6. doi: 10.1111/j.1478-3231.2008.01882.x.

PMID:
19323782
3.

Prevalence, virology and antiviral drugs susceptibility of hepatitis B virus rtN238H polymerase mutation from 1865 Chinese patients with chronic hepatitis B.

Zhong Y, Lv J, Li J, Xing X, Zhu H, Su H, Chen L, Zhou X.

Antiviral Res. 2012 Jan;93(1):185-90. doi: 10.1016/j.antiviral.2011.11.012. Epub 2011 Nov 26.

PMID:
22138714
4.

Prevalence, viral replication efficiency and antiviral drug susceptibility of rtQ215 polymerase mutations within the hepatitis B virus genome.

Amini-Bavil-Olyaee S, Herbers U, Mohebbi SR, Sabahi F, Zali MR, Luedde T, Trautwein C, Tacke F.

J Hepatol. 2009 Oct;51(4):647-54. doi: 10.1016/j.jhep.2009.04.022. Epub 2009 May 27.

PMID:
19586679
5.

[Genotype distribution of chronic hepatitis B and hepatitis C patients and investigation of the resistance patterns in hepatitis B cases].

Kalayci R, Altindiş M, Gülamber G, Demirtürk N, Akcan Y, Demirdal T.

Mikrobiyol Bul. 2010 Apr;44(2):237-43. Turkish.

PMID:
20549958
6.
7.

Genotypic resistance profile of hepatitis B virus (HBV) in a large cohort of nucleos(t)ide analogue-experienced Chinese patients with chronic HBV infection.

Liu Y, Wang C, Zhong Y, Li X, Dai J, Ren X, Xu Z, Li L, Yao Z, Ji D, Wang L, Zhang L, Wong VW, Zoulim F, Xu D.

J Viral Hepat. 2011 Apr;18(4):e29-39. doi: 10.1111/j.1365-2893.2010.01360.x. Epub 2010 Sep 6.

PMID:
21392168
8.
9.

Monitoring of therapy in patients with chronic hepatitis B virus.

Arrese E, Basaras M, Blanco S, Ruiz P, Cisterna R.

Eur J Gastroenterol Hepatol. 2010 Jun;22(6):736-40. doi: 10.1097/MEG.0b013e32832e0a44.

PMID:
19550344
10.

Evolution of full-length HBV sequences in chronic hepatitis B patients with sequential lamivudine and adefovir dipivoxil resistance.

Chen CH, Lee CM, Tung WC, Wang JH, Hung CH, Hu TH, Wang JC, Lu SN, Changchien CS.

J Hepatol. 2010 Apr;52(4):478-85. doi: 10.1016/j.jhep.2010.01.006. Epub 2010 Feb 2.

PMID:
20185198
11.

Rescue therapy for lamivudine-resistant chronic hepatitis B: adefovir monotherapy, adefovir plus lamivudine or entecavir combination therapy.

Ha M, Zhang G, Diao S, Lin M, Wu J, Sun L, She H, Shen L, Huang C, Shen W, Huang Z.

Intern Med. 2012;51(12):1509-15. Epub 2012 Jun 15.

12.

Impact of the rtI187V polymerase substitution of hepatitis B virus on viral replication and antiviral drug susceptibility.

Fan J, Wang Y, Xiong H, Guo X, Cheng YC.

J Gen Virol. 2014 Nov;95(Pt 11):2523-30. doi: 10.1099/vir.0.066886-0. Epub 2014 Jul 15.

13.

Rescue therapy for lamivudine-resistant chronic hepatitis B: comparison between entecavir 1.0 mg monotherapy, adefovir monotherapy and adefovir add-on lamivudine combination therapy.

Kim HJ, Park JH, Park DI, Cho YK, Sohn CI, Jeon WK, Kim BI.

J Gastroenterol Hepatol. 2010 Aug;25(8):1374-80. doi: 10.1111/j.1440-1746.2010.06381.x.

PMID:
20659226
14.

Evolution of hepatitis B virus during long-term therapy in patients with chronic hepatitis B.

Arrese E, Basaras M, Blanco S, Ruiz P, Cisterna R.

Ann Hepatol. 2011 Oct-Dec;10(4):434-40.

15.

[Clinical analysis of hepatitis B virus mutations related to adefovir dipivoxil among patients with chronic hepatitis B virus infection in eastern Zhejiang province].

Hu AR, Jiang SW, Li L, Ding SX, Hu YR, Liang XY.

Zhonghua Yi Xue Za Zhi. 2012 Jul 17;92(27):1878-81. Chinese.

PMID:
23134956
16.

Lamivudine and adefovir resistance in children and young adults with chronic hepatitis B.

Akman SA, Kose S, Halicioglu O.

Int J Infect Dis. 2010 Mar;14(3):e236-9. doi: 10.1016/j.ijid.2009.04.002. Epub 2009 Aug 7.

17.

[Entecavir resistance in entecavir naive lamivudine treated chronic hepatitis B patients].

Sayan M, Hülagü S, Akhan SC, Sentürk O, Meriç M, Cekmen M.

Mikrobiyol Bul. 2009 Jul;43(3):425-32. Turkish.

PMID:
19795617
18.

rtL180M mutation of hepatitis B virus is closely associated with frequent virological resistance to adefovir dipivoxil therapy.

Lee YS, Chung YH, Kim JA, Jin YJ, Park WH, Kim SE, Lee D, Shim JH, Kim KM, Lim YS, Lee HC, Lee YS, Suh DJ.

J Gastroenterol Hepatol. 2012 Feb;27(2):300-5. doi: 10.1111/j.1440-1746.2011.06853.x.

PMID:
21777282
19.

Adefovir dipivoxil treatment of lamivudine-resistant chronic hepatitis B.

Dai CY, Chuang WL, Hsieh MY, Lee LP, Huang JF, Hou NJ, Lin ZY, Chen SC, Hsieh MY, Wang LY, Tsai JF, Chang WY, Yu ML.

Antiviral Res. 2007 Aug;75(2):146-51. Epub 2007 Mar 16.

PMID:
17400303
20.

Profile of HBV antiviral resistance mutations with distinct evolutionary pathways against nucleoside/nucleotide analogue treatment among Chinese chronic hepatitis B patients.

Yang JX, Liu BM, Li XG, Yan CH, Xu J, Sun XW, Wang YH, Jiao XJ, Yan L, Dong JP, Hou CS, Abuduheilili X, Li T, Zhuang H.

Antivir Ther. 2010;15(8):1171-8. doi: 10.3851/IMP1677.

PMID:
21149924

Supplemental Content

Support Center